Health Condition 1: null- ASA 1 and 2 patients undergoing lumbosacral spine surgeries Health Condition 2: G998- Other specified disorders of nervous system in diseases classified elsewhere
Conditions
Interventions
Intervention1: Ropivacaine: 25 ml of 0.2% Ropivacaine single shot in the caudal space after patient is put prone for surgery(20 minutes prior to skin incision)
Control Intervention1: Levobupivacaine:
Sponsors
Self
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients who give written informed consent 2) ASA 1 and 2 patients 3) Aged between 18 to 50 years 4) Body Mass Index 18.9 to 24.9 kg/m2
Exclusion criteria
Exclusion criteria: 1) Patient refusal 2) Patients with systemic illnesses 3) Patients with sacral anomaly or undergone previous spine surgery or those with pre existing neurological deficits 4) Patients with drug allergies 5) Patients with contraindication for neuraxial techniques
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Isoflurane consumption intraoperatively 2) Duration and quality of analgesiaTimepoint: 1) Isoflurane consumption noted every half an hour intraoperatively and total consumption at the end of surgery 2) Duration and quality of analgesia postoperatively every half hourly till patient demands additional analgesic or visual analogue score is more than 4 | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess safety profile of Ropivacaine and LevobupivacaineTimepoint: Throughout during study period | — |
Countries
India
Contacts
Public ContactDr Swathi N
Bangalore Medical College and Research Institute
Outcome results
None listed